328,698 Shares in Annexon, Inc. (NASDAQ:ANNX) Purchased by Walleye Capital LLC

Walleye Capital LLC acquired a new stake in Annexon, Inc. (NASDAQ:ANNX - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 328,698 shares of the company's stock, valued at approximately $1,946,000. Walleye Capital LLC owned approximately 0.31% of Annexon as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in ANNX. Sandia Investment Management LP bought a new position in Annexon in the 2nd quarter valued at $49,000. Victory Capital Management Inc. acquired a new position in Annexon during the 2nd quarter valued at about $51,000. Principal Financial Group Inc. purchased a new stake in Annexon in the second quarter valued at about $56,000. Comerica Bank acquired a new stake in Annexon in the first quarter worth about $72,000. Finally, Allegheny Financial Group LTD increased its holdings in shares of Annexon by 16.1% during the second quarter. Allegheny Financial Group LTD now owns 25,200 shares of the company's stock valued at $123,000 after acquiring an additional 3,500 shares in the last quarter.

Annexon Stock Down 2.7 %

Shares of ANNX traded down $0.14 during midday trading on Thursday, reaching $5.02. The company had a trading volume of 434,480 shares, compared to its average volume of 1,795,640. The firm has a 50 day simple moving average of $6.54 and a 200-day simple moving average of $5.97. The stock has a market cap of $535.10 million, a PE ratio of -4.91 and a beta of 1.10. Annexon, Inc. has a 1-year low of $2.27 and a 1-year high of $8.40.

Analyst Upgrades and Downgrades

ANNX has been the subject of a number of research analyst reports. Cantor Fitzgerald restated an "overweight" rating on shares of Annexon in a research note on Friday, November 15th. HC Wainwright restated a "buy" rating and set a $30.00 price target on shares of Annexon in a research report on Friday, November 15th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $16.00 target price on shares of Annexon in a research note on Friday, November 15th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $15.80.

Insiders Place Their Bets

In other news, EVP Ted Yednock sold 4,500 shares of the company's stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $7.10, for a total value of $31,950.00. Following the transaction, the executive vice president now owns 71,365 shares of the company's stock, valued at $506,691.50. This represents a 5.93 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 12.67% of the stock is owned by insiders.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.